Myosteatosis in nonalcoholic fatty liver disease: An exploratory study

Munck, Toon J.I. De; Lodewick, Toine M.; Bakers, Frans C. H.; Jonkers, Daisy; Masclee, Ad; Verbeek, Jef; Koek, Ger H.

doi:10.1016/j.clinre.2020.06.021

Cited by 14 publications

(16 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, this issue is leveled out by the use of CT-SMI, as this gold standard index is scaled on height thus not directly influenced by obesity. The results on the association of myosteatosis and liver fibrosis also contrasts with recent data on MAFLD in which the authors do not find a link between the muscle fat fraction measured with chemical shift gradient echo MRI and liver stiffness 37 . However, the muscle fat fraction was calculated in one region of interest without any adjustment to the muscular surface 37 .…”

Section: Discussioncontrasting

confidence: 99%

Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients

Lanthier

Rodriguez

Nachit

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Obesity could lead to metabolic dysfunction-associated fatty liver disease (MAFLD), which severity could be linked to muscle and gut microbiota disturbances. Our prospective study enrolled 52 obese patients whose MAFLD severity was estimated by transient elastography. Patients with severe steatosis (n = 36) had higher ALAT values, fasting blood glucose levels as well as higher visceral adipose tissue area and skeletal muscle index evaluated by computed tomography. Patients with fibrosis (n = 13) had higher ASAT values, increased whole muscle area and lower skeletal muscle density index. In a multivariate logistic regression analysis, myosteatosis was the strongest factor associated with fibrosis. Illumina sequencing of 16S rRNA gene amplicon was performed on fecal samples. The relative abundance of fecal Clostridium sensu stricto was significantly decreased with the presence of liver fibrosis and was negatively associated with liver stiffness measurement and myosteatosis. In addition, 19 amplicon sequence variants were regulated according to the severity of the disease. Linear discriminant analysis effect size (LEfSe) also highlighted discriminant microbes in patients with fibrosis, such as an enrichment of Enterobacteriaceae and Escherichia/Shigella compared to patients with severe steatosis without fibrosis. All those data suggest a gut-liver-muscle axis in the pathogenesis of MAFLD complications.

show abstract

Section: Discussioncontrasting

confidence: 99%

Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients

Lanthier

Rodriguez

Nachit

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Forty-five subjects were included in the present study as previously described [17]. All participants had proven NAFLD via liver biopsy or chemical shift magnetic resonance imaging (MRI).…”

Section: Subject Characteristicsmentioning

confidence: 99%

“…Then, the ROI was copied from the in-phase (IP) image to the opposed-phase (OP) image. The mean signal intensity (SI) loss of all 12 ROIs was calculated as previously described [17,20].…”

Section: Magnetic Resonance Imaging (Mri) -Hepatic Fat Fractionmentioning

confidence: 99%

“…MRI images were obtained with a 1.5T or 3T Achieva MRI system (Philips, Best, The Netherlands). The muscle fat fraction was measured with the simultaneously obtained 3D fast gradient echo mDixon images as previously described [17]. Parameters employed for 3D fast gradient echo mDixon sequence were for 1.5T and 3T respectively: flip angle = 15° and 10°, TR = 5.8 and 3.4 ms, TE1/TE2 = 2.37/4.75 and 1.19/2.37ms, field-of-view (FOV) = 320 x 320 and 384 x 384 mm, acquisition matrix = 288 x 227 and 252 x 209, slice thickness 5 and 3 mm.…”

Section: Magnetic Resonance Imaging (Mri) -Muscle Fat Fractionmentioning

confidence: 99%

“…Therefore, our study aim was to investigate whether, besides the liver, also the muscle correlates with plasma CTSD levels in NAFLD patients. For this reason, fortyfive NAFLD patients were enrolled in this study, in which muscle signal intensity loss on in-phase and opposedphase imaging (chemical shift MRI) was assessed to determine myosteatosis based on the formula as previously described [17]. Furthermore, fasting blood samples were analyzed for the measurement of glucoseand lipid-related parameters, liver enzymes as well as plasma CTSD levels.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Myosteatosis in NAFLD patients correlates with plasma Cathepsin D

Ding

Munck

Oligschlaeger

et al. 2021

Biomolecular Concepts

Self Cite

View full text Add to dashboard Cite

Previously, we have shown that hepatic lipid accumulation induces the secretion of cathepsin D (CTSD), and that plasma CTSD levels are associated with increased inflammation and disease severity in nonalcoholic fatty liver disease (NAFLD). Although it is clear that the liver is a major source of plasma CTSD, it is unknown whether other metabolically active organs such as the muscle, also associate with plasma CTSD levels in NAFLD patients. Therefore, the aim of this study was to explore the relation between lipid accumulation in the muscle (myosteatosis) and plasma CTSD levels in forty-five NAFLD patients. We observed that hepatic steatosis positively associated with plasma CTSD levels, confirming the previously established link between plasma CTSD and the liver. Furthermore, a positive association between myosteatosis and plasma CTSD levels was observed, which was independent of sex, age, BMI, waist circumference and hepatic steatosis. By establishing a positive association between myosteatosis and plasma CTSD levels, our findings suggest that, in addition to the liver, the muscle is also linked to plasma CTSD levels in NAFLD patients. The observed link between myosteatosis and plasma CTSD levels supports the concept of a significant role of the skeletal muscle in metabolic disturbances in metabolic syndrome-related disorders.

show abstract

Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography

Kim,

Cho,

Kim

et al. 2024

J cachexia sarcopenia muscle

View full text Add to dashboard Cite

BackgroundIn 2023, the concept of metabolic dysfunction‐associated steatotic liver disease (MASLD) was introduced as an alternative to non‐alcoholic fatty liver disease (NAFLD). We aimed to assess the quantity and quality of skeletal muscle using each of these diagnostic classifications.MethodsThis cross‐sectional study included 18 154 participants (11 551 [63.6%] men and 6603 [36.4%] women, mean age 53.0 ± 8.8). The participants were classified into four categories: neither steatotic liver disease (SLD), NAFLD only, MASLD only or both SLDs. An appendicular skeletal muscle mass adjusted for body mass index of <0.789 for men and <0.512 for women was defined as sarcopenia. The total abdominal muscle area (TAMA) at the L3 vertebral level was segmented into normal‐attenuation muscle area (NAMA), low‐attenuation muscle area and intermuscular/intramuscular adipose tissue. Myosteatosis was defined by a T‐score < −1.0 of the NAMA/TAMA index, which was calculated by dividing the NAMA by the TAMA and multiplying by 100.ResultsUsing subjects with neither SLD as a reference, the multivariable‐adjusted odds ratios (ORs) for sarcopenia were significantly increased in those with MASLD, with adjusted ORs (95% confidence interval [CI]) of 2.62 (1.94–3.54) in the MASLD‐only group and 2.33 (1.92–2.82) in the both SLDs group, while the association was insignificant in those with NAFLD only (adjusted OR [95% CI]: 2.16 [0.67–6.94]). The OR for myosteatosis was also elevated in the MASLD groups, with an OR (95% CI) of 1.75 (1.52–2.02) in subjects with MASLD only and 1.70 (1.57–1.84) in those with both SLDs, while it was slightly decreased in subjects with NAFLD only (0.52 [0.29–0.95]).ConclusionsEmploying the MASLD concept rather than that of the NAFLD proved to be more effective in distinguishing individuals with reduced muscle mass and compromised muscle quality.

show abstract

Myosteatosis in nonalcoholic fatty liver disease: An exploratory study

Cited by 14 publications

References 40 publications

Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients

Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients

Myosteatosis in NAFLD patients correlates with plasma Cathepsin D

Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography

Contact Info

Product

Resources

About